SIGA Technologies, Inc.
Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: SIGA Technologies, Inc. |
Ticker: | Ticker: SIGA |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA). The investigation concerns whether SIGA and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On September 23, 2024, SIGA disclosed that its Chief Medical Officer and Executive Vice President, Dr. Jay Varma, had been terminated from his position. On this news, the price of SIGA shares declined by $0.42, or approximately 5%, from $8.43 on September 23, 2024, to close at $8.01 per share on September 24, 2024.
On September 25, 2024, a secretly recorded video surfaced online, revealing Varma detailing a media “spin” campaign to salvage the Company’s antiviral medication TPOXX as a treatment for Monkeypox so that investors would not “dump the stock, thinking that the Company is worthless,” despite the admission that “in the United States, the risk [for Monkeypox] is very low.” On this news, the price of SIGA shares declined by $1.26, or approximately 15.7%, from $8.01 on September 24, 2024, to close at $6.75 per share on September 25, 2024, thereby injuring investors further.
On September 23, 2024, SIGA disclosed that its Chief Medical Officer and Executive Vice President, Dr. Jay Varma, had been terminated from his position. On this news, the price of SIGA shares declined by $0.42, or approximately 5%, from $8.43 on September 23, 2024, to close at $8.01 per share on September 24, 2024.
On September 25, 2024, a secretly recorded video surfaced online, revealing Varma detailing a media “spin” campaign to salvage the Company’s antiviral medication TPOXX as a treatment for Monkeypox so that investors would not “dump the stock, thinking that the Company is worthless,” despite the admission that “in the United States, the risk [for Monkeypox] is very low.” On this news, the price of SIGA shares declined by $1.26, or approximately 15.7%, from $8.01 on September 24, 2024, to close at $6.75 per share on September 25, 2024, thereby injuring investors further.